Moving toward multi-dimensional biomarkers in cancer immunotherapy

Max Jameson-Lee, Jason J. Luke

Abstract

The development of anti-programmed death 1 (PD1) antibodies has rapidly changed standard oncology clinical practice however only a fraction of patients benefit from these treatments and some tumor types remain unresponsive.

Article Options

Download Citation